Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ETNB 
89bio Inc (ETNB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ETNB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $29.45
1 Year Target Price $29.45
| 8 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.07% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.44B USD | Price to earnings Ratio - | 1Y Target Price 29.45 |
Price to earnings Ratio - | 1Y Target Price 29.45 | ||
Volume (30-day avg) 11 | Beta 1.53 | 52 Weeks Range 4.16 - 11.84 | Updated Date 06/30/2025 |
52 Weeks Range 4.16 - 11.84 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.93% | Return on Equity (TTM) -69.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 836743192 | Price to Sales(TTM) - |
Enterprise Value 836743192 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.75 | Shares Outstanding 145984000 | Shares Floating 101584553 |
Shares Outstanding 145984000 | Shares Floating 101584553 | ||
Percent Insiders 0.61 | Percent Institutions 108.89 |
Analyst Ratings
Rating 4 | Target Price 29.45 | Buy 1 | Strong Buy 8 |
Buy 1 | Strong Buy 8 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
89bio Inc
Company Overview
History and Background
89bio Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardio-metabolic diseases. It was founded in 2018. The company is progressing its lead product candidate, pegozafermin, through clinical development.
Core Business Areas
- Drug Development: Focuses on the development of pegozafermin for NASH and severe hypertriglyceridemia (SHTG).
Leadership and Structure
Dr. Roham Zamanpour is the CEO. The company has a board of directors and a management team focused on clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Pegozafermin: Pegozafermin is a fibroblast growth factor 21 (FGF21) analogue being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). It does not currently have market share as it is in clinical trials. Competitors include companies developing NASH and SHTG treatments, such as Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investments in research and development. Liver and cardio-metabolic diseases represent a large and growing market opportunity.
Positioning
89bio is positioned as a clinical-stage company focused on NASH and SHTG. Its competitive advantage relies on the potential efficacy and safety profile of pegozafermin.
Total Addressable Market (TAM)
The total addressable market for NASH is estimated to be in the tens of billions of dollars. The SHTG market is also significant. 89bio is positioned to capture a portion of these markets if pegozafermin is approved.
Upturn SWOT Analysis
Strengths
- Promising clinical trial data for pegozafermin
- Experienced management team
- Focus on underserved markets (NASH and SHTG)
Weaknesses
- Clinical-stage company with no approved products
- Reliance on a single product candidate (pegozafermin)
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing NASH and SHTG treatments
- Patent challenges
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- AKRO
Competitive Landscape
The competitive landscape is crowded, with numerous companies developing treatments for NASH and SHTG. 89bio needs to differentiate itself with superior efficacy, safety, or convenience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by clinical trial progress and stock price volatility based on trial results and market sentiment.
Future Projections: Future growth is dependent on the successful development and commercialization of pegozafermin.
Recent Initiatives: Recent initiatives include advancing pegozafermin through clinical trials and exploring potential partnerships.
Summary
89bio is a clinical-stage biopharmaceutical company with a focus on NASH and SHTG. Its future hinges on the success of pegozafermin, which has shown promise in clinical trials. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition. Recent stock performance has been poor and the company needs to show positive data to reverse this trend.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 89bio Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2019-11-11 | CEO & Director Mr. Rohan Palekar | ||
Sector Healthcare | Industry Biotechnology | Full time employees 93 | Website https://www.89bio.com |
Full time employees 93 | Website https://www.89bio.com | ||
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.